Truist Financial Upgrades Adicet Bio (NASDAQ:ACET) to “Strong-Buy”

Adicet Bio (NASDAQ:ACET) was upgraded by Truist Financial to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other research firms have also recently issued reports on ACET. HC Wainwright decreased their price objective on shares of Adicet Bio from $50.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday. Guggenheim cut their target price on Adicet Bio from $128.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Adicet Bio in a report on Tuesday, January 27th. Finally, Canaccord Genuity Group set a $18.00 price target on Adicet Bio and gave the company a “buy” rating in a research report on Tuesday, January 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Adicet Bio Stock Performance

Shares of Adicet Bio stock opened at $6.81 on Wednesday. Adicet Bio has a 52-week low of $6.41 and a 52-week high of $17.44. The stock has a market capitalization of $65.38 million, a price-to-earnings ratio of -0.38 and a beta of 1.56. The company’s 50 day moving average price is $7.43 and its 200-day moving average price is $9.80.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($2.94) EPS for the quarter, beating analysts’ consensus estimates of ($3.23) by $0.29. As a group, equities research analysts forecast that Adicet Bio will post -1.39 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new stake in shares of Adicet Bio in the 3rd quarter worth about $33,000. Squarepoint Ops LLC purchased a new position in shares of Adicet Bio during the third quarter valued at about $38,000. FNY Investment Advisers LLC bought a new position in Adicet Bio in the fourth quarter worth about $51,000. Virtu Financial LLC bought a new position in Adicet Bio in the third quarter worth about $65,000. Finally, Wealthedge Investment Advisors LLC lifted its holdings in Adicet Bio by 37.4% in the second quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock worth $191,000 after buying an additional 85,307 shares during the period. 83.89% of the stock is currently owned by institutional investors.

More Adicet Bio News

Here are the key news stories impacting Adicet Bio this week:

• Positive Sentiment: HC Wainwright raised near-term and full-year 2026 EPS forecasts (Q1–Q4 and FY), trimming projected losses (e.g., Q1 est. now ($2.80) vs prior ($2.91); FY2026 now ($11.58) vs ($12.17)) and reiterated a “Buy” rating with a $27 price target — signals improved analyst sentiment and a large implied upside versus the current share price. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Zacks upgraded ACET to a Zacks Rank #2 (Buy), citing improving earnings prospects — upgrades from recognized research services can attract buying interest and short-term momentum. Adicet Bio (ACET) Upgraded to Buy: Here’s Why
• Neutral Sentiment: Reported short-interest data for March shows anomalous “0 shares” and NaN changes across multiple filings — the numbers appear unreliable or misreported, so there is no clear evidence of elevated short pressure based on the available data. (Monitor future filings for corrected short-interest figures.)
• Negative Sentiment: An AmericanBankingNews headline framed HC Wainwright’s coverage as a “pessimistic forecast” for ACET stock price — conflicting media spin can add volatility even when analyst estimates are being trimmed toward smaller losses. HC Wainwright Issues Pessimistic Forecast for Adicet Bio (NASDAQ:ACET) Stock Price

Adicet Bio Company Profile

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.